Welcome to our dedicated page for Lantern Pharma news (Ticker: LTRN), a resource for investors and traders seeking the latest updates and insights on Lantern Pharma stock.
Lantern Pharma Inc. (Symbol: LTRN) is at the forefront of innovation in the realm of cancer treatment, striving to deliver the most effective therapies to patients who are poised to benefit the most. The company employs a pioneering precision medicine approach to cancer treatment, leveraging biomarker-based genetic screening to identify and treat patients who would derive the greatest benefit from their drugs. This method not only reduces the cost of drug development but also expedites the time to market.
Lantern Pharma's core business revolves around its proprietary artificial intelligence (AI) and machine learning (ML) platform, RADR. The RADR platform assimilates oncology-focused data points and utilizes advanced ML algorithms to address complex, billion-dollar challenges in cancer drug development. This innovative platform has significantly accelerated the company's growing pipeline of precision therapies, with input from world-class scientific advisors and collaborators.
In addition to its in-house development, Lantern Pharma adopts a strategic approach by acquiring or partnering with promising drug and diagnostic companies. This strategy is aimed at advancing personalized medicine programs for cancer patients, thus broadening the company's impact in the oncology space.
With a commitment to transforming the cost, pace, and timeline of oncology drug discovery and development, Lantern Pharma continues to make strides in the development of precision therapies. The company's recent achievements and ongoing projects underscore its potential to revolutionize cancer treatment and deliver significant value to both patients and stakeholders.
Lantern Pharma announced a collaboration with TTC Oncology to utilize its AI platform, RADR®, in advancing the clinical development of TTC-352, a selective human estrogen receptor partial agonist (ShERPA) for metastatic ER+ breast cancer. This innovative drug candidate is positioned as first-in-class, targeting patients who have failed previous therapies. As part of the agreement, Lantern gains exclusive licensing rights to TTC-352 and any resulting intellectual property. The partnership aims to leverage over 25 billion oncology-focused data points and advanced machine learning algorithms for patient selection and drug development insights, enhancing potential market reach.
Lantern Pharma Inc. (NASDAQ: LTRN) is enhancing its RADR® platform to support the development of Antibody Drug Conjugates (ADCs). This initiative aims to advance ADC candidates to first-in-human trials in around two years, bolstered by a library of over 200 algorithms and 25 billion oncology-focused data points. The ADC market, currently valued at over $4 billion, is projected to grow to $14 billion by 2027. The expansion includes new AI and ML strategies for drug candidate identification, patient stratification, and improved payload delivery, positioning Lantern for significant business development opportunities.
Lantern Pharma (NASDAQ: LTRN) has received FDA guidance for its LP-184 program aimed at treating various cancers, including CNS cancers. The feedback aligns with Lantern's plans for an IND submission and a first-in-human clinical trial scheduled for Q2 2023. LP-184 demonstrates significant potency against multiple cancers and aims to improve outcomes for patients with high unmet needs. The trial will focus on pancreatic cancer and glioblastoma, leveraging Lantern's RADR® AI platform for patient identification. The company anticipates impactful results that could benefit both patients and shareholders.
Lantern Pharma (NASDAQ: LTRN) announced that the FDA has granted Orphan Drug Designation for LP-284, aimed at treating mantle cell lymphoma (MCL). This designation enhances LP-284’s clinical development and offers seven years of market exclusivity. Lantern expects to file an IND and begin a Phase 1 trial for LP-284 in MCL by mid-2023. MCL affects around 4,500 patients annually in the U.S., with a market potential of $600 million. The drug demonstrated significant anti-tumor activity in preclinical models, particularly against resistant tumors.
Lantern Pharma (NASDAQ: LTRN) released positive preclinical data for LP-284, targeting Mantle Cell Lymphoma (MCL), presented at the American Society of Hematology Meeting. The data indicates LP-284's superior tumor growth inhibition compared to traditional therapies like Ibrutinib and Bortezomib, achieving a TGI of 113%. Lantern plans to file an IND with the FDA in early 2023 and initiate a Phase 1 trial mid-2023. MCL and double hit lymphoma (DHL) represent about 9,000 new cases annually, with a market potential of $1.2 billion USD.
Lantern Pharma Inc. (NASDAQ: LTRN) announced significant findings at the SABCS 2022, highlighting the promising anti-tumor effects of its drug candidate LP-184 against Triple Negative Breast Cancer (TNBC). LP-184 demonstrated an average IC50 of 297nM across four TNBC cell lines and achieved a remarkable 107-141% tumor regression in 10 resistant tumor models. The annual market for TNBC represents approximately
Lantern Pharma (NASDAQ: LTRN) announced that CEO Panna Sharma will present at the RHK Capital Disruptive Growth Conference in New York City on December 5, 2022, at 12:00 p.m. ET. This conference will showcase around 30 innovative companies, connecting them with institutional and accredited investors.
Lantern Pharma leverages its RADR® AI platform for oncology drug development, focusing on genomically-targeted therapies, with four candidates in progress.
Lantern Pharma (NASDAQ: LTRN) announced positive preclinical data for its drug candidate LP-184 targeting glioblastoma (GBM) at the Society for Neuro-Oncology annual meeting. The study showed LP-184's efficacy either alone or combined with spironolactone, outperforming the standard treatment Temozolomide (TMZ) in resistant models. LP-184 has the potential market of $1.5-2.0 billion, with ongoing collaborative research with Johns Hopkins aimed at advancing it to clinical trials in 2023. The drug holds Orphan Drug and Rare Pediatric Disease designations, emphasizing its potential in oncology.
Lantern Pharma (NASDAQ: LTRN) reported third quarter results for 2022, activating two sites for the Harmonic™ clinical trial in never-smoker patients with NSCLC. The completion of IND-enabling studies for LP-184 and LP-284 is anticipated in Q1 2023, with Phase 1 trials planned for H1 2023. As of September 30, 2022, Lantern held $57.8 million in cash, reflecting a net decrease of $4.3 million during the quarter. Despite a net loss of $2.3 million, a significant reduction from $4.1 million year-over-year, the company maintains a cash runway into 2025.
Lantern Pharma (NASDAQ: LTRN), a clinical-stage biopharmaceutical company, announced its participation in two investor conferences. The BioFuture Conference will take place in New York, NY on November 8, 2022, with presentations by CEO Panna Sharma and CFO David Margrave at 2:00 p.m. ET. The Disruptive Growth Conference is set for December 5-6, 2022, with the time for Sharma's presentation to be announced. Lantern Pharma is advancing oncology drug discovery through its proprietary RADR® platform, targeting customized therapeutics for diverse tumor profiles.
FAQ
What is the current stock price of Lantern Pharma (LTRN)?
What is the market cap of Lantern Pharma (LTRN)?
What does Lantern Pharma Inc. specialize in?
What is the RADR platform?
How does Lantern Pharma's approach reduce drug development costs?
What is the company's strategy for growth?
How does Lantern Pharma use AI in drug development?
Who are the key collaborators with Lantern Pharma?
What are some of Lantern Pharma's recent achievements?
Why is precision medicine important in cancer treatment?
How does Lantern Pharma's strategy benefit cancer patients?
What is the significance of biomarker-based genetic screening?
